<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:regn="http://regeneron.com/20230327">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_regn_regeneron.com_20230327 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20230327_20230327 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="regn-20230327.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-03-27to2023-03-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-27</xbrli:startDate>
        <xbrli:endDate>2023-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20230327__20230327_zhtXumxhdhe3"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
March 29, 2023 (<span id="xdx_908_edei--DocumentPeriodEndDate_c20230327__20230327_zgwHcMM7BmJ"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">March 27, 2023</ix:nonNumeric></span></b><b>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20230327__20230327_zZeGZMhNwW39"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20230327__20230327_zMwOty7ugJ27"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(State or other
jurisdiction of incorporation)</b></span></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20230327__20230327_zITYG8jY3CU1"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20230327__20230327_z3ZgwKpv3cOh"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(Commission</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>File Number)</b></span></p></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>(I.R.S.
                                    Employer</b></span></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>Identification
        No.)</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20230327__20230327_zUXvdJkYXeva"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20230327__20230327_zRaDsvPQNesi"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20230327__20230327_zxuymsDCAnEl"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20230327__20230327_zEoFLZumKCC7"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Address
    of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>(Zip
    Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_901_edei--CityAreaCode_c20230327__20230327_zJmoqIv1n3L1"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20230327__20230327_zqVb10nHb755"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90B_edei--WrittenCommunications_c20230327__20230327_zkq93DhRk1C7"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20230327__20230327_zm9T5qneMyrf"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20230327__20230327_ztzOmERYbLfl"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20230327__20230327_zsHhYD8N0Toc"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="border-bottom: Black medium double; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Title
    of each class</span></i></span></td>
    <td style="font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Trading
    Symbol(s)</span></i></span></td>
    <td style="font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><i><span style="text-decoration: underline">Name
    of each exchange on which <br />
    registered</span></i></span></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20230327__20230327_zOLohyYQMK69"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:Security12bTitle">Common stock &#8211; par value $.001 per share</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20230327__20230327_zXBm5tSMJ2u5"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 1pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20230327__20230327_zytdFK1SA6ul"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20230327__20230327_zL7vbmf7DnO6"><ix:nonNumeric contextRef="From2023-03-27to2023-03-27" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 48pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>I</i></b></span><b><i>tem 1.01.</i></b></td>
  <td style="text-align: justify"><b><i>Entry into a Material Definitive Agreement.</i></b></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">On March 27, 2023,
Regeneron Pharmaceuticals, Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) and/or certain of its subsidiaries
amended and restated (i) the Second Amended and Restated Participation Agreement, dated as of March 2, 2022, and effective as of March
3, 2022 (the &#8220;<span style="text-decoration: underline">Second A&amp;R Participation Agreement</span>&#8221; and, as so amended and restated, the &#8220;<span style="text-decoration: underline">Third A&amp;R
Participation Agreement</span>&#8221;), by and among Old Saw Mill Holdings LLC, a wholly owned subsidiary of the Company (the &#8220;<span style="text-decoration: underline">Lessee</span>&#8221;),
Bank of America, N.A., as administrative agent (in such capacity, the &#8220;<span style="text-decoration: underline">Administrative Agent</span>&#8221;), BA Leasing BSC, LLC,
an affiliate of Banc of America Leasing &amp; Capital, LLC, as lessor (in such capacity, the &#8220;<span style="text-decoration: underline">Lessor</span>&#8221;), and a syndicate
of financial institutions as rent assignees (collectively with the Lessor, the &#8220;<span style="text-decoration: underline">Participants</span>&#8221;), which Second A&amp;R
Participation Agreement had amended and restated the Amended and Restated Participation Agreement that was entered into on May 2, 2019
(the &#8220;<span style="text-decoration: underline">First A&amp;R Participation Agreement</span>&#8221;) to amend and restate the Participation Agreement originally entered into
on March 3, 2017 (the &#8220;<span style="text-decoration: underline">Original Participation Agreement</span>,&#8221; and as amended and restated by the First A&amp;R Participation
Agreement and the Second A&amp;R Participation Agreement, the &#8220;<span style="text-decoration: underline">Previously Existing Participation Agreement</span>&#8221;); and (ii)
certain related agreements that were originally entered into in March 2017 and subsequently amended and restated in each of May 2019 and
March 2022 (as previously amended and restated, and together with the Previously Existing Participation Agreement, collectively, the &#8220;<span style="text-decoration: underline">Previously
Existing Agreements</span>&#8221;). The Previously Existing Agreements provided for a $720.0 million lease financing that was originally
completed on March 3, 2017 for the Company&#8217;s corporate headquarters and other rentable area consisting of approximately 150 acres
of predominately office buildings and laboratory space located in the towns of Mount Pleasant and Greenburgh, New York (the &#8220;<span style="text-decoration: underline">Facility</span>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">As described in greater
detail below, the Third A&amp;R Agreements (as defined below) amended and restated the Previously Existing Agreements, among other things,
in order to revise certain covenants, representations and warranties, and events of default to be substantially similar to those set forth
in the Credit Agreement, dated as of December 19, 2022 (the &#8220;<span style="text-decoration: underline">Credit Agreement</span>&#8221;), by and among Regeneron, as a borrower
and guarantor, certain subsidiaries of Regeneron as subsidiary borrowers, JPMorgan Chase Bank, N.A., as administrative agent, and the
lenders party thereto from time to time. The Company&#8217;s entry into the Credit Agreement was previously reported in its Current Report
on Form 8-K filed with the United States Securities and Exchange Commission on December 20, 2022. The Third A&amp;R Agreements did not
change the maturity date of the advances under the Second A&amp;R Participation Agreement or the term of the Second A&amp;R Lease (as
defined below). The yield that is payable to the Participants on their outstanding advances under the Second A&amp;R Participation Agreement
also remains unchanged under the Third A&amp;R Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Third A&amp;R Participation Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">On March 27 2023,
the Lessee entered into the Third A&amp;R Participation Agreement with the Administrative Agent, the Lessor, and the other Participants,
which amends and restates the Second A&amp;R Participation Agreement. The Third A&amp;R Participation Agreement and certain related documents
govern the $720.0 million lease financing that was previously advanced in March 2017 to finance the purchase price for the Facility and
to reimburse the Company for certain payments previously made by it in connection with such acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Third A&amp;R Lease</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">In connection with the
Third A&amp;R Participation Agreement, the Lessee also entered into a Third Amended and Restated Lease and Remedies Agreement, dated
as of March 27, 2023 (the &#8220;<span style="text-decoration: underline">Third A&amp;R Lease</span>&#8221;), with the Lessor, which amends and restates the Lessee&#8217;s
lease of the Facility and certain related assets that was originally entered into in March 2017 by the Lessee and the Lessor and
previously amended and restated on May 2, 2019, pursuant to the Amended and Restated Lease and Remedies Agreement, and on March 2,
2022, pursuant to the Second Amended and Restated Lease and Remedies Agreement (the &#8220;<span style="text-decoration: underline">Second A&amp;R Lease</span>&#8221;).
Pursuant to the Second A&amp;R Lease, the term of the lease was extended for a five-year period ending in March 2027. Pursuant to
the Third A&amp;R Lease, the Lessee continues to grant a security interest in certain of its assets and rights to secure certain
obligations under the Third A&amp;R Agreements and certain related documents. The Third A&amp;R Lease continues to be a triple-net
lease requiring the Lessee, among other things, to pay during the term of the Third A&amp;R Lease all maintenance, insurance, taxes,
and other costs arising out of the use of the Facility (which are offset in part by payments received by the Lessee from third-party
tenants to whom certain parts of the Facility are subleased from the Lessee). The Third A&amp;R Lease also continues to require that
the Lessee make monthly payments of basic rent during the remaining term of the Third A&amp;R Lease in an amount equal to the yield
payable to the Participants on their outstanding advances under the Third A&amp;R Participation Agreement. Such advances continue to
accrue yield at a variable rate per annum based on the one-month forward-looking Secured Overnight Financing (SOFR) term rate, plus
a spread adjustment, plus an applicable margin that varies with the Company&#8217;s debt rating and total leverage ratio.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third A&amp;R Guaranty</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">The
Company continues to guarantee all of the Lessee&#8217;s obligations under the Third A&amp;R Participation Agreement, the Third A&amp;R
Lease, and certain related documents pursuant to a Third Amended and Restated Guaranty, dated as of March 27, 2023 (the &#8220;<span style="text-decoration: underline">Third
A&amp;R Guaranty</span>,&#8221; and together with the Third A&amp;R Participation Agreement and the Third A&amp;R Lease, collectively, the
&#8220;<span style="text-decoration: underline">Third A&amp;R Agreements</span>&#8221;), made by the Company and its wholly owned subsidiaries, Regeneron Healthcare Solutions,
Inc. and Regeneron Genetics Center LLC, each as a subsidiary guarantor (together with other subsidiaries of the Company (other than certain
excluded subsidiaries), collectively, &#8220;<span style="text-decoration: underline">Subsidiary Guarantors</span>&#8221; and, each, a &#8220;<span style="text-decoration: underline">Subsidiary Guarantor</span>&#8221;).
The Third A&amp;R Guaranty provides that a Subsidiary Guarantor will become jointly and severally liable with the Company as a guarantor
under the Third A&amp;R Guaranty only at such time as such Subsidiary Guarantor has an outstanding borrowing under the Credit Agreement.
As of the date hereof, no Subsidiary Guarantor has any outstanding borrowing under the Credit Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Financial and Operating Covenants; Other
Terms</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">The Third A&amp;R
Agreements contain operating covenants and a maximum total leverage ratio financial covenant, which are substantially similar to the covenants
set forth in the Credit Agreement, except for such matters specifically relating to the Facility or the lease financing nature of the
transactions contemplated by the Third A&amp;R Agreements. Operating covenants include, among other things, limitations on (i) the incurrence
of certain indebtedness by the Company&#8217;s subsidiaries, (ii) certain liens on assets of the Company and its subsidiaries and liens
on the Facility, and (iii) certain fundamental changes and the disposition of assets by the Company and its subsidiaries. The Third A&amp;R
Agreements contain other customary covenants, representations and warranties, and events of default. The Third A&amp;R Lease also continues
to include certain early termination events relating to the occurrence of certain material events of loss or material environmental events
relating to the Facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><b><i>Maturity Date; Additional Extension Option;
Termination</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">Pursuant to the Third A&amp;R
Agreements, March 3, 2027 continues to be the maturity date for the $720.0 million advances and the end of the term of the Lessee&#8217;s
lease of the Facility from the Lessor, at which time all amounts outstanding thereunder will become due and payable in full. The Third
A&amp;R Participation Agreement and the Third A&amp;R Lease include an option for the Lessee to elect to extend the maturity date of the
Third A&amp;R Participation Agreement and the term of the Third A&amp;R Lease for an additional five-year period, subject to the consent
of all the Participants and certain other conditions. The Lessee also has the option prior to the end of the term of the Third A&amp;R
Lease to (a) purchase the Facility by paying an amount equal to the outstanding principal amount of the Participants&#8217; advances under
the Third A&amp;R Participation Agreement, all accrued and unpaid yield thereon, and all other outstanding amounts under the Third A&amp;R
Agreements and certain related documents or (b) sell the Facility to a third party on behalf of the Lessor, in each case, subject to certain
terms and conditions set forth in the Third A&amp;R Participation Agreement and the Third A&amp;R Lease. Outstanding advances under the
Third A&amp;R Participation Agreement and outstanding obligations under the Third A&amp;R Lease may be prepaid at any time without premium
or penalty, subject to customary breakage costs. The expiration date and the extension term of the Third A&amp;R Agreements described in this paragraph remain the same as the corresponding
expiration date and extension term of the Previously Existing Agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">* * *</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">The foregoing description
of the Third A&amp;R Participation Agreement, the Third A&amp;R Lease, and the Third A&amp;R Guaranty is qualified in its entirety by
reference to the full and complete text of such agreements, copies of which are attached hereto as Exhibits 10.1, 10.2, and 10.3, respectively,
and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 48pt"><b><i>Item 2.03.</i></b></td><td style="text-align: justify"><b><i>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
of a Registrant.</i></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 16.2pt">The information
set forth in Item 1.01 above with respect to the Third A&amp;R Agreements is hereby incorporated by reference into this Item 2.03 insofar
as it relates to the creation of a direct financial obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 48pt"><b><i>Item 9.01.</i></b></td><td style="text-align: justify"><b><i>Financial Statements and Exhibits.</i></b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="width: 15%; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b><span style="text-decoration: underline">Exhibit No.</span></b></span></td>
<td style="text-align: justify; width: 85%"><b><span style="text-decoration: underline">Description</span></b> <b>&#160;</b></td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt; text-align: justify">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt"><a href="tm2310647d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.1*</span></a></td>
<td style="text-align: justify"><a href="tm2310647d1_ex10-1.htm" style="-sec-extract: exhibit">Third Amended and Restated Participation Agreement, dated as of March 27, 2023, by and among Old Saw Mill Holdings LLC, as lessee, Bank of America, N.A., as administrative agent, BA Leasing BSC, LLC, as lessor, and the rent assignees party thereto from time to time.</a></td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt"><a href="tm2310647d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.2*</span></a></td>
<td style="text-align: justify"><a href="tm2310647d1_ex10-2.htm" style="-sec-extract: exhibit">Third Amended and Restated Lease and Remedies Agreement, dated as of March 27, 2023, between Old Saw Mill Holdings LLC, as lessee, and BA Leasing BSC, LLC, as lessor.</a></td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">&#160;</td>
<td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt"><a href="tm2310647d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">10.3*</span></a></td>
<td style="text-align: justify; font-size: 10pt"><a href="tm2310647d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Third Amended and Restated Guaranty, dated as of March 27, 2023, made by Regeneron Pharmaceuticals, Inc., Regeneron Healthcare Solutions, Inc., and Regeneron Genetics Center LLC, as guarantors.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="font-size: 10pt">&#160;</td>
<td style="text-align: justify; font-size: 10pt">&#160;</td></tr>
<tr style="vertical-align: top">
<td>104</td>
<td style="text-align: justify">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">*&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain of the
exhibits and/or schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish
supplementally a copy of all omitted exhibits and schedules to the Securities and Exchange Commission upon its request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
<td style="vertical-align: top; width: 50%"><b>&#160;</b></td>
<td style="width: 50%"><b>REGENERON PHARMACEUTICALS, INC.&#160; &#160;</b></td>
</tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td>&#160;</td>
</tr>
<tr>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid">/s/ Joseph J. LaRosa</td>
</tr>
<tr>
<td>&#160;</td>
<td style="font-size: 10pt"><span style="font-size: 10pt">Joseph J. LaRosa</span></td>
</tr>
<tr>
<td>&#160;</td>
<td style="font-size: 10pt"><span style="font-size: 10pt">Executive Vice President, General Counsel and Secretary</span></td>
</tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 29, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 21pt 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
